Recombinant Proteins

Recombinant Proteins(重组蛋白)

Recombinant proteins are a new combination of genes that forms DNA. Recombinant DNA technology allows for the production of wild type and modified human and mammalian proteins at bulk quantities. Recombinant proteins are made from cloned DNA sequences which usually encode an enzyme or protein with known function

Recombinant proteins are made through genetic engineering, also called gene splicing or recombinant DNA technology. By putting human, animal or plant genes into the genetic material of bacteria, mammalian or yeast cells, these microorganisms can be used as factories or producers to make proteins for medical, academic and research uses.

A vector is simply a tool for manipulating DNA and can be viewed as a "transport vehicle" for the production of proteins from specific DNA sequences cloned into them. Purification and expression of a protein can sometimes be quite complicated & time-consuming, therefore an additional tag is used in addition to the specific DNA sequence which will facilitate the purification & expresion of the recombinant protein.

Recombinant Proteins are proteins that their DNA that has been created artificially. DNA from 2 or more sources which is incorporated into a single recombinant molecule. The DNA is first treated with restriction endonuclease enzyme which the ends of the cut have an overhanging piece of single-stranded DNA. These are called "sticky ends" because they are able to base pair with any DNA molecule containing the complementary sticky end. DNA ligase covalently links the two strands into 1 recombinant DNA molecule.

Recombinant DNA molecule must be replicated many times to provide material for analysis & sequencing. Producing many identical copies of the same recombinant DNA molecule is called cloning. Cloning is done in vitro, by a process called the polymerase chain reaction (PCR). Cloning in vivo can be done in unicellular microbessuch as E. coli, unicellular eukaryotes like yeast and in mammalian cells grown in tissue culture.

Recombinant DNA must be taken up by the cell in a form in which it can be replicated and expressed. This is achieved by incorporating the DNA in a vector. A number of viruses (both bacterial and of mammalian cells) can serve as vectors.

Recombinant DNA is also sometimes referred to as chimera. When combining two or more different strands of DNA.There are 3 different methods by which Recombinant DNA is made. 1. Transformation, 2. Phage-Transfection 3.Yeast, Plant & Mammalian Transformation. When using the method of transformation one needs to select a piece of DNA to be inserted into a vector, cut a piece of DNA with a restriction enzyme and ligate the DNA insert into the vector with DNA Ligase. The insert contains a selectable marker which allows for identification of recombinant molecules. An antibiotic marker is used in order to cause death for a host cell which does not contain the vector when exposed to a certain antibiotic.

Trasnformation is the insertion of the vector into the host cell. The host cells are prepared to take up the foreign DNA. Selectable markers are used for antibiotic resistance, color changes, or any other characteristic which can distinguish transformed hosts from untransformed hosts. Yeast, Plant & Mammalian Transformation is done by micro-injecting the DNA into the nucleus of the cell being transformed. Phage-Transfection process, is equivalent to transformation except for the fact that phage lambda or MI3 is used instead of bacteria.

These phages produce plaques which contain recombinant proteins which can be easily distinguished from the non-recombinant proteins by various selection methods.

Significant amounts of recombinant protein are produced by the host only when expression genes are added. The Protein’s expression depends on the genes which surround the DNA of interest, this collection of genes act as signals which provide instructions for the transcription and translation of the DNA of interest by the cell. These signals include the promoter, ribosome binding site, and terminator.

The recombinant DNA is inserted into expression vectors which contain the promoter, ribosome binding site, and terminator.

In prokaryotic systems, the promoter, ribosome binding site, and terminator have to be from the same host since the bacteria is unlikely to understand the signals of human promoters and terminators. The designated gene must not contain human introns since the bacteria does not recognize it and this results in premature termination, and the recombinant protein may not be processed correctly, be folded correctly, or may even be degraded.

The peptide sequence can be added as an extension at the N-terminal. Researchers can select the specific purification system which they would like to use. The unique vectors available contain several features needed for the production of bulk quantities of the target protein. The peptide sequence is usually placed in the vector so that it is designed to be a point of attack for a specific protease. Thus, after the recombinant protein is expressed and extracted from bacteria, specific peptide extension can be used to purify the protein and subsequently removed from the target protein to generate a nearly natural sequence on the final product.

6 or more consistent Histidine residues act as a metal binding site for recombinant protein purification and expression. The hexa-His sequence is called a His-Tag sequence which can be placed on the N-terminal of a target protein by using vectors from various commercial molecular biology companies. The His-Tag contains a cleavage site for a specific protease. His-Tag recombinant proteins are purified by Metal Chelate Affinity Chromatography such as nickel ion columns that are used as the heavy metal ion and the His-Tag protein is eluted from the metal-chelate column with Histidine or imidazole. Then the purified His-Tag protein is treated with the specific protease to cleave off the His-Tag or not if the tag doesn’t affect the active site of the protein.

Proteins have metal binding sites which can be used for the purification of recombinant and natural proteins. This type of purification is rather simple when using a gel bead which is covalently modified so that it displays a chelator group for binding a heavy metal ion like Ni2+ or Zn2+. The chelating group on the gel bead contains a small amount of the ligands needed to hold the metal ion. So when the protein’s metal binding site finds the heavy metal, it will bind by providing the ligands from its metal binding site to attach to the metal ion displayed on the chelator location of the gel bead. This purification method is quite identical to affinity chromatography when purifying metal-binding class of proteins.

研究方向

Recombinant Proteins 相关产品(2687)

  • GC60077 structure
    GC60077BIO5192 hydrate
    纯度: >99.50%

    BIO5192hydrate是一种选择性强的整合素α4β1(VLA-4)抑制剂(Kd<10pM)。BIO5192hydrate选择性地与α4β1(IC50=1.8nM)结合,选择性高过其他一系列整合素。BIO5192hydrate导致小鼠造血干细胞和祖细胞(HSPCs)的动员比基础水平增加30倍。

  • GC60117 structure
    GC60117Cyclo(-RGDfK) TFA
    CAS: 500577-51-5
    纯度: >99.50%

    An inhibitor of αvβ3 integrin

  • GC60172 structure
    GC60172Gardenia yellow
    CAS: 94238-00-3

    Gardenia yellow是一种常用的天然食用色素,具有良好的水溶性特性。

  • GC60183 structure
    GC60183GSK2245035
    CAS: 1207629-49-9
    纯度: >99.50%

    A TLR7 agonist

  • GC60200 structure
    GC60200ILK-IN-3
    CAS: 6975-75-3
    纯度: >99.50%

    ILK-IN-3 is an integrin linked kinase (ILK) inhibitor with antitumor activity.

  • GC61109 structure
    GC61109Natalizumab
    CAS: 189261-10-7
    纯度: >99.00%

    Natalizumab是一种重组的人源化单克隆抗体,与α4β1-整联蛋白(α4β1-integrin)结合并阻断其与血管细胞粘附分子1(VCAM-1)的相互作用。Natalizumab可用于复发缓解型多发性硬化症和克罗恩氏病的研究。Natalizumab也可阻止淋巴细胞进入中枢神经系统,从而防止急性脱髓鞘复发。

  • GC61279 structure
    GC61279SIRT-IN-3
    CAS: 1211-19-4
    纯度: >99.00%

    SIRT-IN-3是一种有效的SIRT抑制剂,对SIRT1的IC50为17μM。SIRT-IN-3对SIRT1的选择性分别是SIRT-2和SIRT3的4倍和14倍(IC50forSIRT2=74μM;IC50forSIRT3=235μM)。

  • GC61323 structure
    GC61323Tetrac
    CAS: 67-30-1
    纯度: >98.00%

    Tetrac(Tetraiodothyroaceticacid),L-甲状腺素(T4)的天然衍生物,是甲状腺素整合素受体拮抗剂。Tetrac阻断T4和3,5,3'-triiodo-L-thyronine(T3)在整联蛋白αvβ3上甲状腺激素的细胞表面受体处的作用。Tetra具有抗血管生成和抗肿瘤活性。

  • GC61367 structure
    GC61367VAF347
    CAS: 574759-62-9
    纯度: >99.50%

    VAF347是一种细胞可渗透且高度亲和力的芳烃受体(AhR)激动剂,可诱导AhR信号传导。VAF347抑制颗粒单核细胞(GM期)前体中CD14+CD11b+单核细胞的发育。VAF347具有抗炎作用。

  • GC61520 structure
    GC61520Cilengitide TFA
    CAS: 199807-35-7
    纯度: >99.50%

    An integrin αVβ3 receptor antagonist

  • GC61613 structure
    GC61613Integrin modulator 1
    CAS: 2023788-32-9
    纯度: >99.00%

    Integrinmodulator1是一种有效和选择性的α4β1整联蛋白激动剂,IC50值为9.8nM。Integrinmodulator1增加了α4β1整联蛋白介导的细胞粘附,EC50值为12.9nM。

  • GC61783 structure
    GC61783BMS-309403 sodium
    CAS: 2802523-05-1
    纯度: >98.50%

    A cell- permeable, potent, and selective inhibitor of FABP4

  • GC62128 structure
    GC62128Bractoppin
    CAS: 2290527-07-8
    纯度: >99.00%

    Bractoppin 是一种串联 BRCT(串联 BRCT,BRCA1),由人乳腺癌和卵巢癌抑制蛋白 (BRCA1) tBRCT 结构域识别磷酸肽的药物样抑制剂,在体外选择性抑制底物结合的纳摩尔活性,IC50 为0.074 77777#181;M。

  • GC62143 structure
    GC62143Carotegrast methyl
    CAS: 401905-67-7
    纯度: >99.50%

    Carotegrast methyl (AJM300) 是一种口服有效和选择性 α4 整联蛋白 (α4 integrin) 拮抗剂。HCA2969 是 Carotegrast methyl 的活性代谢产物,是一种特异的双重 α4β1/α4β7 整联蛋白拮抗剂。Carotegrast methyl 可预防小鼠结肠炎。

  • GC62182 structure
    GC62182Echistatin TFA
    纯度: >95.00%

    Echistatin TFA 最初是来自蛇毒崩素家族中最小的 RGD 活性蛋白,是一种有效的血小板聚集的抑制剂。Echistatin 是体外骨吸收的有效抑制剂。Echistatin 是有效的αIIbβ3、αvβ3 和α5β1 的拮抗剂。

  • GC62380 structure
    GC62380&#945;v&#946;1 integrin-IN-1
    CAS: 1689540-62-2

    αvβ1 integrin-IN-1 (Compound C8) 是一种有效的选择性 αvβ1 整合素抑制剂,IC50 为 0.63 nM。具有抗纤维化作用。

  • GC62397 structure
    GC62397RO0270608
    CAS: 220846-33-3
    纯度: >98.50%

    RO0270608,是 R411 的活性代谢物,是一种双重 alpha4beta1-alpha4beta7 (α4β1/α4β7) 整合素拮抗剂。具有抗炎活性。

  • GC62566 structure
    GC62566&#945;v&#946;1 integrin-IN-1 TFA
    纯度: >98.00%

    αvβ1 integrin-IN-1 TFA (Compound C8) 是一种有效的选择性 αvβ1 整合素抑制剂,IC50 为 0.63 nM。具有抗纤维化作用。

  • GC62617 structure
    GC62617FABP-IN-1
    CAS: 2132990-90-8
    纯度: >98.00%

    FABP-IN-1(Compounds 4b) 是一种高亲和力脂肪酸结合蛋白 (FABP) 抑制剂。FABP-IN-1 抑制 FABP3,FABP5 和 FABP7 的 Ki 值分别为 0.69 μM,0.55 μM 和 0.67 μM,并具有有效的镇痛作用。

  • GC62651 structure
    GC626517-Chloro-4-(piperazin-1-yl)quinoline
    CAS: 837-52-5

    7-Chloro-4-(piperazin-1-yl)quinolone 是药物化学中的重要支架。7-Chloro-4-(piperazin-1-yl)quinolone 是有效的 sirtuin 抑制剂,还抑制 5-羟色胺的摄取 (IC50 为 50 μM)。7-Chloro-4-(piperazin-1-yl)quinolone 对恶性疟原虫 D10 和 K1 菌株表现出抗疟疾活性,IC50 分别为 1.18 μM 和 0.97 μM。

  • GC62872 structure
    GC62872BMS-587101
    CAS: 509083-77-6
    纯度: >98.50%

    BMS-587101 是一种有效的具有口服活性的 leukocyte function associated antigen-1 (LFA-1) 拮抗剂。BMS-587101 具有抗炎作用,可用于类风湿关节炎的研究。

  • GC62886 structure
    GC62886Cannabisin F
    CAS: 163136-19-4

    Cannabisin F 是一种 SIRT1 调制器。Cannabisin F 作为大麻籽木素酰胺,可用于抗炎、抗氧化研究。Cannabisin F 作为SIRT1/NF-κB 和 Nrf2 的调节因子,可能是一种潜在的神经退行性疾病的调节剂。

  • GC63165 structure
    GC63165RAD51-IN-1
    CAS: 2101739-18-6
    纯度: >99.50%

    RAD51-IN-1 是 B02 的衍生物,是 RAD51 的有效抑制剂。 RAD51-IN-1 可用于癌症研究。

  • GC63490 structure
    GC63490Valategrast
    CAS: 220847-86-9
    纯度: >98.50%

    Valategrast (R-411 free base) 是一种有效的口服活性整联蛋白 α4β1 (VLA-4) 和 α4β7 双重拮抗剂。Valategrast 可用于慢性阻塞性肺疾病 (COPD) 和哮喘的研究。